2種類の異なる用量のアベンシグアトが、肝硬変および門脈（肝臓につながる主要な血管）の高血圧患者に効果があるかどうかを検証する研究

基本情報

NCT ID

NCT05161481

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

80

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this condition. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of Avenciguat as tablets twice a day. Participants in the placebo group take placebo as tablets twice a day. Placebo tablets look like Avenciguat tablets but do not contain any medicine. Participants are in the study for about 8 months. During this time, they visit the study site about 14 times. At 3 of the visits, the doctors check the pressure in a liver vein. This is done with a catheter (a long thin tube) and gives information about the pressure in the portal vein. The change in blood pressure is then compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

対象疾患

介入

依頼者（Sponsor）

実施施設 (6)